DexCom Inc. (DXCM)

57.12
0.22 0.38
NASDAQ : Health Technology
Prev Close 57.34
Open 57.20
Day Low/High 56.82 / 57.87
52 Wk Low/High 42.62 / 86.32
Volume 823.02K
Avg Volume 1.36M
Exchange NASDAQ
Shares Outstanding 86.90M
Market Cap 4.75B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

UnitedHealthcare And Dexcom Bring Wearable Technology Solution, One-on-One Coaching To People Battling Type 2 Diabetes

UnitedHealthcare And Dexcom Bring Wearable Technology Solution, One-on-One Coaching To People Battling Type 2 Diabetes

UnitedHealthcare, the market leader in Medicare benefit plans 1, and DexCom, Inc.

DexCom Reports Record Preliminary, Unaudited Revenue For The Fourth Quarter And Fiscal Year 2017 And Provides Initial 2018 Outlook

DexCom Reports Record Preliminary, Unaudited Revenue For The Fourth Quarter And Fiscal Year 2017 And Provides Initial 2018 Outlook

DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring ("CGM"), today reported that it achieved preliminary, unaudited revenue of approximately $218 million for the fourth quarter ended December 31, 2017,...

Weekly Roundup

Callout: Fed raises interest rates, stocks grind higher

DexCom Announces Upcoming Conference Presentation

DexCom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conference: Kevin Sayer, President and Chief Executive Officer, will present an...

These Are the Biggest Winners and Losers in Activist Investing This Year

These Are the Biggest Winners and Losers in Activist Investing This Year

TheStreet recounts the successes and failures of the biggest names in the activism game.

Weekly Roundup

Stocks finish higher in an up and down week.

DexCom Announces Upcoming Conference Presentation

DexCom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conference: Quentin Blackford, Executive Vice President, Chief Financial Officer;...

Weekly Roundup

Oil hits highest level since 2015 in holiday-shortened week. We drop a name from the portfolio.

Dexcom, Lilly Team Up on Diabetes System

Companies aim to improve disease management.

Dexcom Announces Development Agreement With Lilly To Integrate Dexcom CGM Into Connected Diabetes Ecosystem

Dexcom Announces Development Agreement With Lilly To Integrate Dexcom CGM Into Connected Diabetes Ecosystem

DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, today announced a development agreement with Eli Lilly and Company (NYSE: LLY) to include Dexcom CGM into Lilly's...

Weekly Roundup

A rebound late in the week helps the markets recover from a bout of selling. We add a name to the portfolio.

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Jim Cramer says don't be too quick to ascribe today's gains just to tax reform. This rally was roaring well before that. Instead, credit Cisco and Wal-Mart Stores.

Comcast, Lululemon, EQT and Other New Activist Investments

Comcast, Lululemon, EQT and Other New Activist Investments

Quarterly filings provide a window into new allocations made by insurgent fund managers Paul Singer, Glenn Welling, Barry Rosenstein and Keith Meister. Could M&A campaigns be next?

DexCom Announces Upcoming Conference Presentation

DexCom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conference: Steven Pacelli, Executive Vice President, Strategy and Corporate...

DexCom Launches "Call Of The Warrior" Campaign For National Diabetes Awareness Month

DexCom Launches "Call Of The Warrior" Campaign For National Diabetes Awareness Month

In honor of National Diabetes Awareness Month, DexCom, Inc. (Nasdaq: DXCM) has launched the "Call of the Warrior" campaign on social media to support those living with diabetes, a chronic disease that affects more than...

DexCom, Inc. Reports Record Third Quarter 2017 Financial Results

DexCom, Inc. Reports Record Third Quarter 2017 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its unaudited financial results as of and for the quarter ended September 30, 2017.

Weekly Roundup

Markets ride a tide of earnings. In the portfolio, we trimmed 3 positions.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: GSK, OPB, RES, SIX, TUP Downgrades: AXS, BPL, DXCM, KRA, OI, TRK, WMS Initiations: NTB Read on to get TheStreet Quant Ratings' detailed report:

DexCom Announces Upcoming Conference Presentation

DexCom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conference: Kevin Sayer, President and Chief Executive Officer, will present an...

DexCom Schedules Third Quarter 2017 Earnings Release And Conference Call For November 1, 2017 At 4:30 P.m. Eastern Time

DexCom Schedules Third Quarter 2017 Earnings Release And Conference Call For November 1, 2017 At 4:30 P.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2017 financial results after market close on Wednesday, November 1, 2017.

The Case for the Bears: Cramer's 'Mad Money' Recap (Wed 10/4/17)

The Case for the Bears: Cramer's 'Mad Money' Recap (Wed 10/4/17)

Wait! What?! Jim Cramer ticks off the potential problems that smart investors should be on the lookout for.

Jim Cramer: We Remain Excited About Abbott Laboratories for Action Alerts Plus

Jim Cramer: We Remain Excited About Abbott Laboratories for Action Alerts Plus

Jim Cramer explains why his Action Alerts Plus charitable portfolio is hanging on to Abbott Laboratories.

Buy Abbott Labs as It Obliterates DexCom Stock, Jim Cramer Says

Buy Abbott Labs as It Obliterates DexCom Stock, Jim Cramer Says

Shares of DexCom are down more than 35% Thursday after Abbott Labs secured FDA approval for its new glucose monitoring system. Jim Cramer calls Abbott Labs a buy.

Noteworthy Thursday Option Activity: DXCM, AQMS, TCX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in DexCom Inc , where a total volume of 6,159 contracts has been traded thus far today, a contract volume which is representative of approximately 615,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 59.6% of DXCM's average daily trading volume over the past month, of 1.0 million shares.

Abbott Climbs on 'Dose' of Good News; Raising Our Target

FDA approval and dosing label for FreeStyle Libre glucose monitoring system makes it a major player in the U.S. market.

DexCom Opens Data Platform And Launches Developer Program To Fuel Diabetes App Innovation

DexCom Opens Data Platform And Launches Developer Program To Fuel Diabetes App Innovation

DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (CGM), announced today the availability of a public API, empowering third-party developers to connect patient-authorized CGM data into a broad range...

DexCom Announces Upcoming Conference Presentation

DexCom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conference: Steven Pacelli, Executive Vice President, Strategy and...

Fitbit And Dexcom To Develop Continuous Glucose Monitoring (CGM) Experience For People Living With Diabetes

Fitbit And Dexcom To Develop Continuous Glucose Monitoring (CGM) Experience For People Living With Diabetes

Fitbit (NYSE:FIT), the leading global wearables brand, and DexCom, Inc.

TheStreet Quant Rating: D (Sell)